Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 200 | 2024 | 21019 | 4.680 |
Why?
|
Mastectomy, Segmental | 60 | 2023 | 963 | 3.380 |
Why?
|
Radiotherapy, Adjuvant | 35 | 2024 | 1785 | 3.220 |
Why?
|
Mastectomy | 41 | 2024 | 1832 | 3.000 |
Why?
|
Neoplasm Recurrence, Local | 94 | 2024 | 9271 | 1.770 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 34 | 2021 | 937 | 1.760 |
Why?
|
Lymph Node Excision | 22 | 2023 | 1304 | 1.450 |
Why?
|
Carcinoma in Situ | 18 | 2016 | 796 | 1.360 |
Why?
|
Carcinoma, Ductal, Breast | 20 | 2016 | 1092 | 1.220 |
Why?
|
Lymph Nodes | 20 | 2024 | 3482 | 1.190 |
Why?
|
Radiation Injuries | 12 | 2017 | 1183 | 1.130 |
Why?
|
Mammaplasty | 10 | 2024 | 1234 | 1.080 |
Why?
|
Radiotherapy, Conformal | 9 | 2014 | 549 | 1.040 |
Why?
|
Combined Modality Therapy | 97 | 2019 | 8548 | 0.930 |
Why?
|
Axilla | 22 | 2023 | 617 | 0.800 |
Why?
|
Lymphatic Metastasis | 44 | 2024 | 2943 | 0.780 |
Why?
|
Lymphatic Irradiation | 5 | 2024 | 115 | 0.740 |
Why?
|
Brachytherapy | 8 | 2017 | 1239 | 0.680 |
Why?
|
Radiation Oncology | 9 | 2017 | 560 | 0.660 |
Why?
|
Radiotherapy | 18 | 2019 | 1503 | 0.630 |
Why?
|
Dermatomyositis | 1 | 2021 | 256 | 0.610 |
Why?
|
Neoplasm Staging | 55 | 2020 | 11125 | 0.590 |
Why?
|
Aromatase Inhibitors | 4 | 2022 | 511 | 0.560 |
Why?
|
Practice Guidelines as Topic | 6 | 2018 | 7460 | 0.540 |
Why?
|
Chemotherapy, Adjuvant | 28 | 2016 | 3518 | 0.530 |
Why?
|
Patient Satisfaction | 5 | 2015 | 3448 | 0.520 |
Why?
|
Female | 218 | 2024 | 390174 | 0.510 |
Why?
|
Sentinel Lymph Node Biopsy | 8 | 2023 | 726 | 0.500 |
Why?
|
Fluorouracil | 10 | 2005 | 1621 | 0.490 |
Why?
|
Tamoxifen | 14 | 2015 | 962 | 0.490 |
Why?
|
Bone Neoplasms | 3 | 2023 | 2532 | 0.480 |
Why?
|
Radiotherapy Dosage | 23 | 2020 | 2895 | 0.470 |
Why?
|
Mastectomy, Radical | 3 | 2003 | 19 | 0.460 |
Why?
|
Humans | 243 | 2024 | 759098 | 0.430 |
Why?
|
Antineoplastic Agents, Hormonal | 9 | 2019 | 1522 | 0.410 |
Why?
|
Breast | 10 | 2023 | 1980 | 0.380 |
Why?
|
Deglutition Disorders | 1 | 2017 | 629 | 0.370 |
Why?
|
Meta-Analysis as Topic | 6 | 2022 | 1374 | 0.370 |
Why?
|
Cyclophosphamide | 9 | 2012 | 2218 | 0.360 |
Why?
|
SEER Program | 6 | 2013 | 1531 | 0.360 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 27 | 2012 | 11656 | 0.350 |
Why?
|
Mastectomy, Modified Radical | 3 | 2000 | 62 | 0.350 |
Why?
|
Wound Healing | 1 | 2021 | 2781 | 0.350 |
Why?
|
Methotrexate | 7 | 2005 | 1715 | 0.320 |
Why?
|
Mastectomy, Simple | 2 | 2007 | 23 | 0.320 |
Why?
|
Seroma | 1 | 2007 | 75 | 0.280 |
Why?
|
Heart | 6 | 2018 | 4391 | 0.280 |
Why?
|
Randomized Controlled Trials as Topic | 18 | 2024 | 10329 | 0.280 |
Why?
|
Middle Aged | 112 | 2024 | 219628 | 0.270 |
Why?
|
Patient Compliance | 2 | 2020 | 2689 | 0.270 |
Why?
|
Radiosurgery | 3 | 2023 | 1341 | 0.260 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 10 | 2013 | 5247 | 0.260 |
Why?
|
Insurance, Liability | 2 | 2017 | 101 | 0.250 |
Why?
|
Aged | 94 | 2024 | 168615 | 0.250 |
Why?
|
Antineoplastic Agents | 10 | 2018 | 13625 | 0.240 |
Why?
|
Carcinoma, Lobular | 3 | 2005 | 489 | 0.240 |
Why?
|
Nitriles | 1 | 2010 | 954 | 0.240 |
Why?
|
Heart Diseases | 2 | 2017 | 2799 | 0.240 |
Why?
|
Lymphedema | 2 | 2023 | 525 | 0.240 |
Why?
|
Treatment Outcome | 44 | 2024 | 64867 | 0.240 |
Why?
|
Triazoles | 1 | 2010 | 904 | 0.230 |
Why?
|
Lung Neoplasms | 14 | 2017 | 13243 | 0.230 |
Why?
|
Markov Chains | 4 | 2020 | 972 | 0.230 |
Why?
|
Doxorubicin | 6 | 2012 | 2202 | 0.230 |
Why?
|
Survival Rate | 22 | 2016 | 12793 | 0.230 |
Why?
|
Neoplasm Invasiveness | 13 | 2018 | 3618 | 0.220 |
Why?
|
Particle Accelerators | 2 | 2003 | 174 | 0.210 |
Why?
|
Patient Selection | 6 | 2013 | 4268 | 0.210 |
Why?
|
Estrogen Antagonists | 1 | 2003 | 152 | 0.210 |
Why?
|
Survival Analysis | 22 | 2011 | 10181 | 0.210 |
Why?
|
Follow-Up Studies | 53 | 2016 | 39213 | 0.200 |
Why?
|
Disease-Free Survival | 14 | 2012 | 6814 | 0.200 |
Why?
|
Societies, Medical | 4 | 2016 | 3890 | 0.200 |
Why?
|
Age Factors | 17 | 2020 | 18391 | 0.200 |
Why?
|
Malpractice | 2 | 2017 | 554 | 0.190 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 4 | 2017 | 1659 | 0.190 |
Why?
|
Postoperative Complications | 5 | 2019 | 15662 | 0.190 |
Why?
|
Pneumonectomy | 6 | 2013 | 1109 | 0.190 |
Why?
|
United States | 19 | 2021 | 72238 | 0.180 |
Why?
|
Medical Oncology | 3 | 2016 | 2309 | 0.180 |
Why?
|
Adult | 88 | 2024 | 219353 | 0.170 |
Why?
|
Neoplasms, Second Primary | 7 | 2012 | 1059 | 0.170 |
Why?
|
Aged, 80 and over | 41 | 2021 | 58864 | 0.170 |
Why?
|
Phyllodes Tumor | 1 | 2019 | 53 | 0.170 |
Why?
|
Prognosis | 36 | 2015 | 29559 | 0.170 |
Why?
|
Postoperative Care | 2 | 2003 | 1476 | 0.170 |
Why?
|
Mediastinum | 3 | 2017 | 265 | 0.170 |
Why?
|
Neoplasms, Multiple Primary | 6 | 2000 | 585 | 0.160 |
Why?
|
Treatment Failure | 11 | 2010 | 2641 | 0.160 |
Why?
|
Receptors, Estrogen | 8 | 2021 | 2201 | 0.160 |
Why?
|
Cost-Benefit Analysis | 6 | 2022 | 5499 | 0.160 |
Why?
|
Adenocarcinoma | 12 | 2012 | 6312 | 0.160 |
Why?
|
Spinal Cord Compression | 1 | 2020 | 235 | 0.160 |
Why?
|
Pneumonia | 2 | 2009 | 2139 | 0.160 |
Why?
|
Ontario | 1 | 2019 | 404 | 0.160 |
Why?
|
Prospective Studies | 23 | 2023 | 54190 | 0.160 |
Why?
|
United States Food and Drug Administration | 2 | 2017 | 1676 | 0.150 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 1998 | 640 | 0.150 |
Why?
|
Receptor, erbB-2 | 4 | 2023 | 2524 | 0.150 |
Why?
|
Antidotes | 1 | 1998 | 139 | 0.150 |
Why?
|
Delivery of Health Care | 1 | 2016 | 5310 | 0.150 |
Why?
|
Age of Onset | 1 | 2004 | 3301 | 0.140 |
Why?
|
Retrospective Studies | 43 | 2019 | 80125 | 0.140 |
Why?
|
Rectal Neoplasms | 6 | 1998 | 1152 | 0.140 |
Why?
|
Medical Device Recalls | 1 | 2017 | 15 | 0.140 |
Why?
|
Decision Support Techniques | 4 | 2021 | 1999 | 0.140 |
Why?
|
Heartburn | 1 | 2017 | 68 | 0.140 |
Why?
|
Leucovorin | 1 | 1998 | 630 | 0.140 |
Why?
|
Time Factors | 22 | 2017 | 40083 | 0.140 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2016 | 878 | 0.140 |
Why?
|
Small Cell Lung Carcinoma | 2 | 2011 | 421 | 0.140 |
Why?
|
Organs at Risk | 1 | 2018 | 358 | 0.130 |
Why?
|
Standard of Care | 1 | 2020 | 551 | 0.130 |
Why?
|
Lung | 3 | 2012 | 9980 | 0.130 |
Why?
|
Clinical Trials as Topic | 10 | 2019 | 8050 | 0.130 |
Why?
|
Equipment Safety | 1 | 2017 | 258 | 0.130 |
Why?
|
Myocardial Ischemia | 1 | 2006 | 2162 | 0.130 |
Why?
|
Decision Making | 4 | 2021 | 3917 | 0.130 |
Why?
|
Product Surveillance, Postmarketing | 2 | 2017 | 450 | 0.130 |
Why?
|
Electrons | 4 | 2006 | 263 | 0.120 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2001 | 549 | 0.120 |
Why?
|
Radiotherapy, High-Energy | 4 | 1992 | 228 | 0.120 |
Why?
|
Rheumatic Diseases | 1 | 2001 | 640 | 0.120 |
Why?
|
Neoplasm Metastasis | 9 | 2009 | 4883 | 0.120 |
Why?
|
Adenocarcinoma, Mucinous | 7 | 2006 | 517 | 0.120 |
Why?
|
Carcinoma | 3 | 1998 | 2335 | 0.120 |
Why?
|
China | 1 | 2020 | 2349 | 0.120 |
Why?
|
Equipment Failure Analysis | 1 | 2017 | 848 | 0.120 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2020 | 801 | 0.110 |
Why?
|
Microsurgery | 1 | 2019 | 789 | 0.110 |
Why?
|
Carcinoma, Large Cell | 2 | 2011 | 113 | 0.110 |
Why?
|
Evidence-Based Medicine | 2 | 2010 | 3694 | 0.100 |
Why?
|
Photons | 2 | 2014 | 580 | 0.100 |
Why?
|
Chi-Square Distribution | 3 | 2017 | 3469 | 0.100 |
Why?
|
Bayes Theorem | 1 | 2020 | 2322 | 0.100 |
Why?
|
Salvage Therapy | 7 | 2019 | 1265 | 0.100 |
Why?
|
Medical Errors | 2 | 2017 | 1254 | 0.100 |
Why?
|
Life Expectancy | 1 | 2018 | 1248 | 0.100 |
Why?
|
Incidence | 12 | 2019 | 21344 | 0.100 |
Why?
|
Proton Pump Inhibitors | 1 | 2017 | 552 | 0.100 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2009 | 88 | 0.100 |
Why?
|
Pain | 2 | 2023 | 5059 | 0.090 |
Why?
|
Paget's Disease, Mammary | 2 | 2003 | 19 | 0.090 |
Why?
|
Palliative Care | 2 | 2023 | 3608 | 0.090 |
Why?
|
Actuarial Analysis | 8 | 1996 | 375 | 0.090 |
Why?
|
Posture | 2 | 2006 | 954 | 0.090 |
Why?
|
Risk Factors | 23 | 2018 | 74167 | 0.080 |
Why?
|
Esthetics | 6 | 2006 | 323 | 0.080 |
Why?
|
Databases, Factual | 4 | 2020 | 8001 | 0.080 |
Why?
|
Radiation Dosage | 3 | 2009 | 1955 | 0.080 |
Why?
|
Risk Assessment | 7 | 2016 | 24049 | 0.080 |
Why?
|
Tumor Burden | 4 | 2018 | 1886 | 0.080 |
Why?
|
Fractures, Bone | 1 | 2020 | 2035 | 0.080 |
Why?
|
Lymphoma | 2 | 2017 | 1898 | 0.080 |
Why?
|
Diabetes Complications | 2 | 2013 | 1342 | 0.070 |
Why?
|
Esophageal Neoplasms | 2 | 1995 | 1655 | 0.070 |
Why?
|
Lymphatic System | 1 | 1989 | 254 | 0.070 |
Why?
|
Gene Expression Profiling | 2 | 2016 | 9372 | 0.070 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2011 | 346 | 0.070 |
Why?
|
Quality of Life | 2 | 2024 | 13285 | 0.070 |
Why?
|
Software | 2 | 2017 | 4421 | 0.070 |
Why?
|
Death Certificates | 1 | 2006 | 167 | 0.060 |
Why?
|
Barrett Esophagus | 1 | 2008 | 490 | 0.060 |
Why?
|
Sigmoid Neoplasms | 3 | 1989 | 54 | 0.060 |
Why?
|
Carcinoma, Medullary | 1 | 2004 | 115 | 0.060 |
Why?
|
Manuals as Topic | 1 | 2003 | 99 | 0.060 |
Why?
|
Proportional Hazards Models | 7 | 2015 | 12526 | 0.050 |
Why?
|
Drug Therapy | 1 | 2006 | 504 | 0.050 |
Why?
|
Case-Control Studies | 3 | 2010 | 21992 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 2 | 2020 | 1719 | 0.050 |
Why?
|
Multivariate Analysis | 8 | 2015 | 12152 | 0.050 |
Why?
|
Advisory Committees | 2 | 2006 | 788 | 0.050 |
Why?
|
Tattooing | 1 | 2003 | 58 | 0.050 |
Why?
|
Biopsy | 6 | 2009 | 6770 | 0.050 |
Why?
|
Linear Models | 3 | 2017 | 5876 | 0.050 |
Why?
|
Multicenter Studies as Topic | 2 | 2000 | 1715 | 0.050 |
Why?
|
Male | 27 | 2021 | 358602 | 0.050 |
Why?
|
Cardiomyopathies | 1 | 1994 | 1939 | 0.050 |
Why?
|
Mathematics | 1 | 2003 | 708 | 0.050 |
Why?
|
Arm | 3 | 1999 | 584 | 0.050 |
Why?
|
Surgical Flaps | 1 | 2010 | 1666 | 0.050 |
Why?
|
Scattering, Radiation | 1 | 2003 | 488 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 6530 | 0.050 |
Why?
|
Statistics, Nonparametric | 2 | 2017 | 2852 | 0.050 |
Why?
|
Mesothelioma | 3 | 1997 | 806 | 0.050 |
Why?
|
Telangiectasis | 2 | 2014 | 76 | 0.050 |
Why?
|
Dactinomycin | 1 | 2001 | 303 | 0.050 |
Why?
|
Breast Implants | 1 | 2024 | 411 | 0.050 |
Why?
|
Career Choice | 1 | 2007 | 755 | 0.040 |
Why?
|
Skin | 1 | 2014 | 4466 | 0.040 |
Why?
|
Edema | 3 | 1999 | 772 | 0.040 |
Why?
|
Laryngeal Neoplasms | 1 | 1984 | 515 | 0.040 |
Why?
|
Prevalence | 1 | 2017 | 15639 | 0.040 |
Why?
|
Teaching | 1 | 2007 | 1161 | 0.040 |
Why?
|
Logistic Models | 4 | 2017 | 13309 | 0.040 |
Why?
|
Fluoroscopy | 1 | 2003 | 944 | 0.040 |
Why?
|
Hormones | 1 | 2022 | 867 | 0.040 |
Why?
|
Preoperative Care | 2 | 1998 | 2256 | 0.040 |
Why?
|
Genes, erbB-2 | 1 | 2019 | 163 | 0.040 |
Why?
|
Immunohistochemistry | 2 | 2015 | 11046 | 0.040 |
Why?
|
Neoadjuvant Therapy | 3 | 2012 | 2810 | 0.040 |
Why?
|
Faculty, Medical | 1 | 2007 | 1185 | 0.040 |
Why?
|
Rectum | 2 | 1997 | 896 | 0.040 |
Why?
|
Risk | 4 | 2019 | 9622 | 0.040 |
Why?
|
Relative Biological Effectiveness | 1 | 2019 | 312 | 0.040 |
Why?
|
Recurrence | 4 | 2010 | 8465 | 0.040 |
Why?
|
Mammography | 5 | 2009 | 2449 | 0.040 |
Why?
|
Product Recalls and Withdrawals | 1 | 2017 | 7 | 0.040 |
Why?
|
Technology, Radiologic | 1 | 2017 | 160 | 0.030 |
Why?
|
Interferon-alpha | 1 | 2001 | 918 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 1998 | 480 | 0.030 |
Why?
|
Models, Economic | 1 | 2020 | 717 | 0.030 |
Why?
|
Mediastinal Neoplasms | 2 | 2010 | 401 | 0.030 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2016 | 190 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2003 | 4893 | 0.030 |
Why?
|
Device Approval | 1 | 2017 | 164 | 0.030 |
Why?
|
Etanidazole | 1 | 1994 | 22 | 0.030 |
Why?
|
Equipment Design | 1 | 2003 | 3529 | 0.030 |
Why?
|
Mass Screening | 2 | 2009 | 5419 | 0.030 |
Why?
|
Epithelial Cells | 1 | 2007 | 3664 | 0.030 |
Why?
|
Cosmetics | 1 | 1996 | 102 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2003 | 2508 | 0.030 |
Why?
|
Equipment and Supplies | 1 | 2017 | 276 | 0.030 |
Why?
|
Leukemia, Radiation-Induced | 1 | 1994 | 39 | 0.030 |
Why?
|
Radiodermatitis | 1 | 2014 | 59 | 0.030 |
Why?
|
Fat Necrosis | 1 | 2014 | 60 | 0.030 |
Why?
|
Postmenopause | 1 | 2003 | 2499 | 0.030 |
Why?
|
Thiophenes | 1 | 1998 | 587 | 0.030 |
Why?
|
Forecasting | 2 | 2012 | 2928 | 0.030 |
Why?
|
Probability | 1 | 2019 | 2474 | 0.030 |
Why?
|
Primary Ovarian Insufficiency | 1 | 1994 | 106 | 0.030 |
Why?
|
Matched-Pair Analysis | 1 | 2013 | 284 | 0.030 |
Why?
|
Medicare | 2 | 2021 | 6763 | 0.030 |
Why?
|
Skin Pigmentation | 1 | 2014 | 277 | 0.020 |
Why?
|
Quinazolines | 1 | 1998 | 1362 | 0.020 |
Why?
|
Pleural Neoplasms | 1 | 1997 | 609 | 0.020 |
Why?
|
Colonic Neoplasms | 3 | 1988 | 2519 | 0.020 |
Why?
|
Colorectal Neoplasms | 2 | 2002 | 6853 | 0.020 |
Why?
|
Neoplasm, Residual | 2 | 2012 | 1007 | 0.020 |
Why?
|
Registries | 2 | 2006 | 8435 | 0.020 |
Why?
|
Peritoneal Neoplasms | 2 | 1988 | 706 | 0.020 |
Why?
|
Hormone Replacement Therapy | 1 | 2016 | 755 | 0.020 |
Why?
|
Comorbidity | 1 | 2005 | 10550 | 0.020 |
Why?
|
Feasibility Studies | 3 | 2014 | 5192 | 0.020 |
Why?
|
Radioisotope Teletherapy | 1 | 1989 | 15 | 0.020 |
Why?
|
Diagnosis-Related Groups | 1 | 1992 | 450 | 0.020 |
Why?
|
Sex Distribution | 1 | 2015 | 2294 | 0.020 |
Why?
|
Cricetinae | 1 | 1993 | 2424 | 0.020 |
Why?
|
Palpation | 1 | 2009 | 166 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2309 | 0.020 |
Why?
|
Vinblastine | 1 | 2010 | 487 | 0.020 |
Why?
|
Clavicle | 1 | 1991 | 224 | 0.020 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2009 | 66 | 0.020 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2009 | 4030 | 0.020 |
Why?
|
Qualitative Research | 1 | 2019 | 2939 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2002 | 7790 | 0.020 |
Why?
|
Technetium Tc 99m Sulfur Colloid | 1 | 1988 | 63 | 0.020 |
Why?
|
Peripheral Nervous System Diseases | 1 | 1994 | 707 | 0.020 |
Why?
|
Cisplatin | 2 | 2010 | 1643 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 3 | 2011 | 36164 | 0.020 |
Why?
|
Sarcoma | 2 | 2002 | 1786 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5778 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 1998 | 3722 | 0.020 |
Why?
|
Colon, Sigmoid | 1 | 1988 | 123 | 0.020 |
Why?
|
Necrosis | 2 | 1992 | 1613 | 0.020 |
Why?
|
Europe | 2 | 1996 | 3427 | 0.020 |
Why?
|
Ultrasonography, Mammary | 1 | 2009 | 247 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 1989 | 1631 | 0.020 |
Why?
|
Receptors, Progesterone | 1 | 2012 | 1122 | 0.020 |
Why?
|
Carboplatin | 1 | 2010 | 789 | 0.020 |
Why?
|
Phosphorus Radioisotopes | 1 | 1987 | 100 | 0.020 |
Why?
|
Radionuclide Imaging | 2 | 1988 | 1974 | 0.020 |
Why?
|
Cohort Studies | 6 | 2011 | 41266 | 0.020 |
Why?
|
Esophagoscopy | 1 | 2008 | 393 | 0.020 |
Why?
|
Medicine | 1 | 2015 | 943 | 0.020 |
Why?
|
Internship and Residency | 1 | 2007 | 5860 | 0.020 |
Why?
|
Propensity Score | 1 | 2013 | 1917 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 1995 | 1645 | 0.020 |
Why?
|
Poisson Distribution | 1 | 2006 | 507 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2003 | 20027 | 0.020 |
Why?
|
Craniopharyngioma | 1 | 1987 | 277 | 0.020 |
Why?
|
Specimen Handling | 1 | 2009 | 707 | 0.010 |
Why?
|
Career Mobility | 1 | 2007 | 256 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 3960 | 0.010 |
Why?
|
Endometrial Neoplasms | 1 | 1994 | 1362 | 0.010 |
Why?
|
Epithelium | 1 | 2008 | 1604 | 0.010 |
Why?
|
Boston | 1 | 2016 | 9274 | 0.010 |
Why?
|
Regression Analysis | 3 | 2000 | 6358 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 1994 | 2635 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 3 | 2003 | 20461 | 0.010 |
Why?
|
Paclitaxel | 1 | 2010 | 1716 | 0.010 |
Why?
|
Methods | 2 | 1997 | 1074 | 0.010 |
Why?
|
Esophagus | 1 | 2008 | 1023 | 0.010 |
Why?
|
Surgery, Plastic | 1 | 1989 | 640 | 0.010 |
Why?
|
Glottis | 1 | 1984 | 214 | 0.010 |
Why?
|
Blood Vessels | 1 | 1988 | 1112 | 0.010 |
Why?
|
Anxiety | 1 | 2016 | 4527 | 0.010 |
Why?
|
Mentors | 1 | 2007 | 661 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2005 | 1631 | 0.010 |
Why?
|
Vocal Cords | 1 | 1984 | 523 | 0.010 |
Why?
|
Length of Stay | 1 | 2013 | 6452 | 0.010 |
Why?
|
Computer Simulation | 1 | 2013 | 6195 | 0.010 |
Why?
|
Analysis of Variance | 2 | 2000 | 6239 | 0.010 |
Why?
|
International Cooperation | 1 | 2005 | 1435 | 0.010 |
Why?
|
Pituitary Neoplasms | 1 | 1987 | 1312 | 0.010 |
Why?
|
Thymidylate Synthase | 1 | 1998 | 72 | 0.010 |
Why?
|
Neoplasms | 2 | 2017 | 22023 | 0.010 |
Why?
|
HT29 Cells | 1 | 1998 | 190 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1998 | 5801 | 0.010 |
Why?
|
Carcinoma, Lewis Lung | 1 | 1998 | 107 | 0.010 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 1994 | 3606 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2012 | 3203 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 1998 | 11891 | 0.010 |
Why?
|
Health Care Costs | 1 | 2009 | 3253 | 0.010 |
Why?
|
Pilot Projects | 2 | 1999 | 8530 | 0.010 |
Why?
|
Abdominal Neoplasms | 1 | 1997 | 286 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 1998 | 2013 | 0.010 |
Why?
|
Thoracic Neoplasms | 1 | 1997 | 266 | 0.010 |
Why?
|
Heart Failure | 1 | 1998 | 11832 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2015 | 25853 | 0.010 |
Why?
|
Drug Interactions | 1 | 1998 | 1422 | 0.010 |
Why?
|
Body Mass Index | 1 | 2011 | 12871 | 0.010 |
Why?
|
Young Adult | 2 | 2011 | 58477 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2009 | 8489 | 0.010 |
Why?
|
Ovarian Neoplasms | 2 | 2002 | 4871 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2011 | 5875 | 0.010 |
Why?
|
Ovariectomy | 1 | 1994 | 611 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2006 | 4922 | 0.010 |
Why?
|
Survivors | 1 | 2002 | 2355 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1998 | 6132 | 0.010 |
Why?
|
Rib Fractures | 1 | 1992 | 130 | 0.010 |
Why?
|
Pericarditis | 1 | 1992 | 136 | 0.010 |
Why?
|
Brachial Plexus | 1 | 1992 | 166 | 0.010 |
Why?
|
Family Health | 1 | 1995 | 1258 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 1998 | 2371 | 0.010 |
Why?
|
Vincristine | 1 | 1991 | 1036 | 0.000 |
Why?
|
Cell Survival | 1 | 1998 | 5793 | 0.000 |
Why?
|
Odds Ratio | 1 | 2000 | 9712 | 0.000 |
Why?
|
Neck | 1 | 1992 | 730 | 0.000 |
Why?
|
Dysgerminoma | 1 | 1986 | 66 | 0.000 |
Why?
|
Prednisone | 1 | 1991 | 1563 | 0.000 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1998 | 10825 | 0.000 |
Why?
|
Animals | 2 | 1998 | 167531 | 0.000 |
Why?
|
Injections, Intravenous | 1 | 1987 | 1384 | 0.000 |
Why?
|
Head and Neck Neoplasms | 1 | 1998 | 2891 | 0.000 |
Why?
|
Predictive Value of Tests | 2 | 1990 | 15262 | 0.000 |
Why?
|
Adolescent | 2 | 2009 | 87551 | 0.000 |
Why?
|
Melanoma | 1 | 2002 | 5690 | 0.000 |
Why?
|
Random Allocation | 1 | 1987 | 2393 | 0.000 |
Why?
|
Prostheses and Implants | 1 | 1989 | 1274 | 0.000 |
Why?
|
Hand | 1 | 1987 | 903 | 0.000 |
Why?
|
Statistics as Topic | 1 | 1987 | 2364 | 0.000 |
Why?
|
Mice, Inbred C57BL | 1 | 1998 | 21892 | 0.000 |
Why?
|
Testicular Neoplasms | 1 | 1986 | 800 | 0.000 |
Why?
|
Emergencies | 1 | 1986 | 1217 | 0.000 |
Why?
|
Physical Examination | 1 | 1985 | 1243 | 0.000 |
Why?
|
Disease Progression | 1 | 1995 | 13470 | 0.000 |
Why?
|
Reoperation | 1 | 1987 | 4286 | 0.000 |
Why?
|
Radiography | 1 | 1987 | 6964 | 0.000 |
Why?
|
Mice | 1 | 1998 | 80993 | 0.000 |
Why?
|
Image Processing, Computer-Assisted | 1 | 1988 | 8936 | 0.000 |
Why?
|
Diagnosis, Differential | 1 | 1986 | 12963 | 0.000 |
Why?
|
Child, Preschool | 1 | 1986 | 41932 | 0.000 |
Why?
|
Child | 1 | 1986 | 79604 | 0.000 |
Why?
|